JP2024513700A5 - - Google Patents

Info

Publication number
JP2024513700A5
JP2024513700A5 JP2023556746A JP2023556746A JP2024513700A5 JP 2024513700 A5 JP2024513700 A5 JP 2024513700A5 JP 2023556746 A JP2023556746 A JP 2023556746A JP 2023556746 A JP2023556746 A JP 2023556746A JP 2024513700 A5 JP2024513700 A5 JP 2024513700A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
acid sequence
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023556746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513700A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2022/050400 external-priority patent/WO2022193017A1/en
Publication of JP2024513700A publication Critical patent/JP2024513700A/ja
Publication of JP2024513700A5 publication Critical patent/JP2024513700A5/ja
Pending legal-status Critical Current

Links

JP2023556746A 2021-03-17 2022-03-16 抗ワクシニアウイルス抗原抗体並びに関連する組成物及び方法 Pending JP2024513700A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163162199P 2021-03-17 2021-03-17
US63/162,199 2021-03-17
US202163195536P 2021-06-01 2021-06-01
US63/195,536 2021-06-01
PCT/CA2022/050400 WO2022193017A1 (en) 2021-03-17 2022-03-16 Anti-vaccinia virus antigen antibodies and related compositions and methods

Publications (2)

Publication Number Publication Date
JP2024513700A JP2024513700A (ja) 2024-03-27
JP2024513700A5 true JP2024513700A5 (cg-RX-API-DMAC7.html) 2025-03-21

Family

ID=83322196

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556746A Pending JP2024513700A (ja) 2021-03-17 2022-03-16 抗ワクシニアウイルス抗原抗体並びに関連する組成物及び方法

Country Status (8)

Country Link
US (1) US20240309070A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308601A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513700A (cg-RX-API-DMAC7.html)
KR (1) KR20240006506A (cg-RX-API-DMAC7.html)
AU (1) AU2022241385A1 (cg-RX-API-DMAC7.html)
CA (1) CA3211935A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023010848A (cg-RX-API-DMAC7.html)
WO (1) WO2022193017A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022002855A (es) * 2019-09-13 2022-06-02 Admare Therapeutics Soc Anticuerpos antiantígenos de virus oncolíticos y métodos de uso de los mismos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075914A2 (en) * 2005-12-22 2007-07-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies against orthopoxviruses
JP2010507362A (ja) * 2006-08-23 2010-03-11 ケルセジーン ファーマ リミテッド ライアビリティ カンパニー 天然痘モノクローナル抗体
MX2022002855A (es) * 2019-09-13 2022-06-02 Admare Therapeutics Soc Anticuerpos antiantígenos de virus oncolíticos y métodos de uso de los mismos.
WO2021016653A1 (en) * 2019-11-22 2021-02-04 Agersens Pty Ltd Wearable electronic collar for animals

Similar Documents

Publication Publication Date Title
Wang et al. Research progress and applications of multivalent, multispecific and modified nanobodies for disease treatment
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
JP2022548043A5 (cg-RX-API-DMAC7.html)
JP4794301B2 (ja) 抗体の製造方法
CN110229232B (zh) 双特异性抗体及其用途
JP7711208B2 (ja) Dll3に対する結合分子及びその使用
EP2788379A1 (en) Pdgf receptor beta binding polypeptides
MX2010011955A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
EP3310816B1 (en) Cys80 conjugated immunoglobulins
JP7433236B2 (ja) 抗葉酸受容体1抗体及びその使用
CN116948035A (zh) 多特异性抗体及其制备和使用方法
JP7099709B2 (ja) ヒト化抗ベイシジン抗体およびその使用
JP2024514109A (ja) 抗cntn4抗体及びその使用
EP4663661A1 (en) Anti-cdh6 antibody and use thereof
CN120943966A (zh) TriAx抗体的组合物及其制备和使用方法
US20230406929A1 (en) Polypeptide constructs binding to cd3
Thran et al. Co-administration of an effector antibody enhances the half-life and therapeutic potential of RNA-encoded nanobodies
CA2799217A1 (en) Recombinantly produced antibodies targeting erbb signaling molecules and methods of use thereof for the diagnosis and treatment of disease
CN117177999A (zh) 一种靶向IL-18Rβ的抗体及其应用
CN118754989B (zh) 一种抗her2纳米抗体及其制备方法和应用
US20230406887A1 (en) Antigen binding domain with reduced clipping rate
CN105229034B (zh) 用于与抗体药物偶联物疗法一起使用的免疫成像剂
JP2023536630A5 (cg-RX-API-DMAC7.html)
JP2023548471A5 (cg-RX-API-DMAC7.html)
KR20240006506A (ko) 항-백시니아 바이러스 항원 항체 및 관련 조성물 및 방법